

DOV Pharmaceutical, Inc...

Posted by the.guard - 02 Mar 2010 13:55

Depression and obesity - DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results For DOV 21,947

DOV Pharmaceutical, Inc...

If you can and wish to, check out sentence 2 of paragraph 7! You may chuckle.

=====
=====

Re: DOV Pharmaceutical, Inc...

Posted by the.guard - 02 Mar 2010 16:19

Actually, someone sent me this link and I thought it was pretty funny! ... But yes, the part about slowly losing my mind is somewhere between the hot-dog and the stand, if you know what I mean (cuz I don't).

Woops. just got an e-mail alert:

You posted an url to an article about DOV Pharmaceuticals. I just went there, and on the right bottom margin is a pritzusdik ad.

So I removed the link and posted the article below (sent to me by 7Up):

=====
=====

Re: DOV Pharmaceutical, Inc...

Posted by the.guard - 02 Mar 2010 16:21

[color=maroon]Depression and obesity - DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results For DOV 21,947

Main Category: Obesity / Weight Loss / Fitness

Also Included In: Depression; Clinical Trials / Drug Trials

Article Date: 10 Aug 2007 - 0:00 PDT

[email to a friend](#) [printer friendly](#) [view / write opinions](#)

Current Article Ratings:

Patient / Public:

4.6 (35 votes)

Health Professional:

4.67 (3 votes)

Article Opinions: 1 posts

DOV Pharmaceutical, Inc. ("DOV" or the "Company") (Pink Sheets: DOVP.PK) today announced Phase Ib results for DOV 21,947, its lead triple reuptake inhibitor ("TRIP") for the treatment of depression and obesity. Preliminary analysis of the study results indicates DOV 21,947 was safe and well-tolerated at the doses examined and produced a significant decline in plasma triglyceride levels. The Company intends to initiate a Phase II study of DOV 21,947 for the treatment of depression in the fourth quarter of this year.

"Prior studies with DOV 21,947 at up to 100 mg per day demonstrated the safety and tolerability of this compound over dosing periods of up to ten days. The goal of this Phase Ib study was to confirm DOV 21,947's safety and tolerability over an eight-week period at escalating doses of up to 150 mg per day. These data give us added confidence in the drug's safety and tolerability

in preparation for our upcoming Phase II trial in patients with major depressive disorder. The significant reductions in plasma triglyceride levels observed during the conduct of this study are consistent with preclinical evidence that DOV 21,947 is able to produce a significant and sustained reduction in both triglyceride levels and body weight in animal models of obesity. These findings underscore the therapeutic versatility of triple reuptake inhibitors such as DOV 21,947," said Dr. Phil Skolnick, President and Chief Scientific Officer of DOV.

This double-blind, placebo-controlled Phase Ib study enrolled 46 male and female subjects. Following a one-week placebo run-in, subjects received either escalating daily doses of 50 mg, 100 mg and 150 mg of DOV 21,947 (31 subjects) or placebo (15 subjects), for a total of eight weeks. The study demonstrated that DOV 21,947 was safe and well-tolerated in this dose range with no reported serious adverse events. The proportion of patients with treatment emergent adverse events was similar in the two treatment groups, with 36% and 47% in the DOV 21,947 and the placebo treated group, respectively. Reported adverse events with greater than 3% incidence in both the DOV 21,947 and placebo treated arms included headache, nausea, diarrhea and dizziness. No other reported adverse event with a greater than 5% incidence was observed in the DOV 21,947 treated subjects. The incidence of subjects that dropped out of the study due to adverse events was 6.5% and 13.3% in the DOV 21,947 and placebo treated group, respectively.

In addition, preliminary analysis of the clinical chemistry laboratory data indicates that DOV 21,947 treated subjects had lowered plasma triglyceride levels compared to placebo treated subjects (p

=====

=====

Re: DOV Pharmaceutical, Inc...

Posted by Dov - 19 Apr 2010 08:46

I just read this rabeinu guard and laughed, too. Thanks. It was *just* what was needed (after falling asleep with my 9yearold at 10 without ma'ariv, and waking up at 3:30 cuz I spilled the negelvasser all over my shoes that were on the floor). It's now 4:41am, the puddle is dry, ZD got a kick in his buttocks, and for the first time since pre-pesach started, it looks like I'll make it on time to Dirshu!

Much love and chuckles,

DOV21,947

PS. I hope I didn't hurt ZD's tush too badly....he may be delicate. I am really worried about him.

=====

=====